ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1123

Long-Term Renal Benefit with Nefecon in Chinese Patients with Primary Immunoglobulin A Nephropathy: Two-Year NefIgArd Trial Results

Session Information

  • Late-Breaking Posters
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Zhang, Hong, Peking University First Hospital, Beijing, China
  • Kristensen, Jens, Calliditas Therapeutics AB, Stockholm, Sweden
  • Stone, Andrew M., Stone Biostatistics Ltd., Crewe, United Kingdom
  • Wang, Bei, Everest Medicines Ltd., Shanghai, China
  • Ying, Lisa H., Everest Medicines Ltd., Shanghai, China
  • Zhu, Zhengying, Everest Medicines Ltd., Shanghai, China

Immunoglobulin A (IgA) nephropathy (IgAN) is most prevalent in people of East Asian ancestry. Nefecon is a novel targeted-release oral budesonide product designed to act in the distal ileum to reduce excess galactose-deficient IgA1 production. The 2-year NefIgArd trial demonstrated that Nefecon 16 mg/day for 9 months led to a statistically significant treatment benefit on estimated glomerular filtration rate (eGFR) with Nefecon vs placebo. Here, we present results for all patients enrolled in NefIgArd from mainland China, including previously unreported patients.


NefIgArd was a global, double-blind Phase 3 study. Patients with primary IgAN on optimized supportive care were randomized 1:1 to 9 months of Nefecon 16 mg/day or placebo, followed by a 15-month observational period off study drug. The 9-month primary endpoint was change in urine protein-creatinine ratio (UPCR). The 2-year primary endpoint was time-weighted average of eGFR over 2 years.


Baseline characteristics of all 62 Chinese patients were similar to the global study population and were balanced across treatment arms. There was a 9.58 mL/min/1.73 m2 (95% CI 1.95, 19.78) treatment benefit in the 2-year primary endpoint with Nefecon vs placebo (3.74 vs 13.32 mL/min/1.73 m2 average eGFR decline, respectively). At 24 months, the mean absolute changes in eGFR from baseline (Fig. 1) suggested that 66% of the eGFR decline observed with placebo could be prevented with 9 months of Nefecon treatment. Mean UPCR reduction was 31% greater at 9 months and 52% greater over 12–24 months with Nefecon vs placebo. No new safety signals were identified.


Compared with placebo, 9 months of Nefecon treatment provided clinically relevant preservation of eGFR and durable proteinuria reduction over 2 years, supporting a disease-modifying effect in Chinese patients with primary IgAN.


  • Commercial Support – Calliditas Therapeutics AB; Everest Medicines Ltd.